Bhushan Akshikar
#195Managing Director
55
Age
30y
Exp
4y
Tenure
4/10
Risk
🎓 B.Pharm · University of Pune
📜 MBA · SPJIMR (S.P. Jain Institute of Management and Research)
🏛️ None
CompensationTBP
Personality
6
Open
7
Cons
5
Extr
6
Agre
4
Neur
Glaxosmi. Pharma
Healthcare · Large Cap
Mature Stable · Bureaucratic
About
Bhushan Akshikar is the Managing Director of Glaxosmi. Pharma, a Large Cap company in the Healthcare sector with a market cap of ₹43K Cr. A Pragmatic leader with 30 years of experience, he is known for data-driven decision-making and organic builder strategy. Prioritizes steady portfolio rationalization and leveraging digital platforms to enhance accessibility within a highly regulated pharma market.
FAQ
What is Bhushan Akshikar's leadership style?
Bhushan Akshikar is classified as a Pragmatic leader. He is data-driven in decision-making, with a shareholder champion motivation and steady-marathon pace of execution.
What is Bhushan Akshikar's educational background?
Bhushan Akshikar holds a B.Pharm from University of Pune and a MBA from SPJIMR (S.P. Jain Institute of Management and Research).
Who is the CEO of Glaxosmi. Pharma?
Bhushan Akshikar is the Managing Director of Glaxosmi. Pharma. He has been with the company for 4 years and in the current role for 4 years.
Leadership DNA
ArchetypePragmatic
MotivationShareholder Champion
CrisisSteady Hand
DecisionData-Driven
GrowthOrganic Builder
PeopleNumbers Driven
InnovationTraditionalist
PaceSteady-Marathon
PurposePurpose-Blended
CustomerMass-Consumer
EmployerSteady Employer
BrandTrusted
FocusDigital Transformation
OrientationDeep Specialist
Leadership Evidence
“Prioritizes steady portfolio rationalization and leveraging digital platforms to enhance accessibility within a highly regulated pharma market.”
⚡ Crisis●●●●○
As MD of GSK Pharma India, he has focused on maintaining consistent supply chains and operational stability through post-pandemic regulatory and market shifts.
🎯 Motivation●●●○○
His leadership emphasizes operational efficiency and margin improvement to drive consistent value for the multinational parent and public shareholders.
👥 People●●●●○
He is widely recognized for a pragmatic, data-driven management style that prioritizes digital transformation and KPI-based operational excellence.
📈 Growth●●●●○
His strategy centers on optimizing the existing product portfolio and leveraging digital tools to improve market penetration rather than large-scale M&A.
💡 Innovation●●●●○
The company relies on a long-standing, stable portfolio of established consumer healthcare products like Sensodyne and Eno rather than aggressive R&D-led drug discovery.
🏃 Pace●●●●●
As a mature consumer healthcare entity, operations are defined by predictable, process-driven cycles focused on brand maintenance and supply chain reliability.
🌱 Purpose●●●●○
The company maintains a strong focus on public health awareness and ESG initiatives integrated into its operational strategy, particularly in vaccine and hygiene education.
🏷️ Brand●●●●●
The company's identity is built on deep-rooted consumer trust in legacy healthcare brands that have been household staples for decades.
🤝 Customer●●●●●
The company's primary revenue drivers are over-the-counter consumer healthcare brands sold directly to millions of households via retail distribution networks.
💼 Employer●●●●○
The organization is known for its stable corporate culture, long-tenured workforce, and structured, predictable career progression typical of a mature multinational subsidiary.
📋 Mandate
Requires a shift toward agile product commercialization and specialized therapy focus to rejuvenate growth in a highly competitive pharmaceutical landscape.
🏢 Culture●●●●○
Compliance-heavy multinational pharmaceutical firm with rigorous global quality and operational standards.
Financials
Revenue FY25₹4K Cr
PAT FY25₹928 Cr
Rev CAGR 5Y4.5%
OPM29.9%
NPM24.9%
ROE47.5%
ROCE50.6%
P/E40.2
Fwd P/E35.4
P/B24
D/E2.1
Promoter75.6%
Institutional8.5%
Mkt Cap₹43K Cr
Compensation
To Be Published
Data being verified from audited reports
